Enlivex Short Term Debt from 2010 to 2024

ENLV Stock  USD 0.93  0.09  10.71%   
Enlivex Therapeutics Short Term Debt yearly trend continues to be fairly stable with very little volatility. Short Term Debt is likely to outpace its year average in 2024. During the period from 2010 to 2024, Enlivex Therapeutics Short Term Debt regression line of quarterly data had mean square error of 19.1 B and geometric mean of  184,261. View All Fundamentals
 
Short Term Debt  
First Reported
2019-03-31
Previous Quarter
341 K
Current Value
336 K
Quarterly Volatility
222.3 K
 
Covid
Check Enlivex Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Enlivex Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 13.3 K, Total Revenue of 0.0 or Research Development of 20.2 M, as well as many indicators such as Price To Sales Ratio of 39.01, Dividend Yield of 0.0 or PTB Ratio of 1.58. Enlivex financial statements analysis is a perfect complement when working with Enlivex Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Enlivex Therapeutics Correlation against competitors.
For more information on how to buy Enlivex Stock please use our How to Invest in Enlivex Therapeutics guide.

Latest Enlivex Therapeutics' Short Term Debt Growth Pattern

Below is the plot of the Short Term Debt of Enlivex Therapeutics over the last few years. It is Enlivex Therapeutics' Short Term Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Enlivex Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Short Term Debt10 Years Trend
Slightly volatile
   Short Term Debt   
       Timeline  

Enlivex Short Term Debt Regression Statistics

Arithmetic Mean231,749
Geometric Mean184,261
Coefficient Of Variation81.24
Mean Deviation148,832
Median123,000
Standard Deviation188,269
Sample Variance35.4B
Range530K
R-Value0.71
Mean Square Error19.1B
R-Squared0.50
Significance0
Slope29,763
Total Sum of Squares496.2B

Enlivex Short Term Debt History

2024427.2 K
2023346 K
2022653 K
2021617 K
2020203 K

About Enlivex Therapeutics Financial Statements

Enlivex Therapeutics investors use historical fundamental indicators, such as Enlivex Therapeutics' Short Term Debt, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Enlivex Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Short Term Debt346 K427.2 K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Enlivex Stock Analysis

When running Enlivex Therapeutics' price analysis, check to measure Enlivex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enlivex Therapeutics is operating at the current time. Most of Enlivex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Enlivex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enlivex Therapeutics' price. Additionally, you may evaluate how the addition of Enlivex Therapeutics to your portfolios can decrease your overall portfolio volatility.